Medivir AB (MVIRb.F): Epiphany Biosciences, Inc. Announces Positive Results from Its Phase 2b Trial in Shingles
11/19/2009 9:26:44 AM
More...
|
Epiphany Biosciences, Inc. Announces Positive Results from Its Phase 2b Trial in Shingles
11/18/2009 11:59:26 AM
More...
|
Epiphany Biosciences, Inc. Initiates Program to Assess Valomaciclovir (EPB-348) as Adjunctive Therapy in Multiple Sclerosis (MS)
3/24/2009 10:06:23 AM
More...
|
Dr. Charles Sanders to Become Lead Director of Epiphany Biosciences, Inc.
10/3/2008 11:15:32 AM
More...
|
Epiphany Biosciences, Inc. to Continue Phase 2 Shingles Study After Interim Analysis; Plans Follow-On Clinical Trial Studying Post-Herpetic Neuralgia
9/9/2008 6:32:59 AM
More...
|
Epiphany Biosciences, Inc. Reports Initiation of Phase 2 Study of Valomaciclovir for the Treatment of Acute Infectious Mononucleosis
12/7/2007 6:33:13 AM
More...
|
Epiphany Biosciences, Inc. Has Initiated Enrollment in Shingles Study with Valomaciclovir (MIV-606, EBP-348) Licensed From Medivir AB (MVIRb.F)
11/8/2007 10:33:50 AM
More...
|
Epiphany Biosciences, Inc. Reports Initiation and Enrollment in Valomaciclovir Study for Shingles
11/7/2007 7:07:49 AM
More...
|
Epiphany Biosciences, Inc. Announces Appointments to Its Board of Directors
3/30/2007 12:08:51 PM
More...
|
Medivir AB (MVIRb.F) Receives Shares and Cash Payment from Epiphany Biosciences, Inc.
3/19/2007 1:07:25 PM
More...
|
|